Tiotropium bromide [Spiriva; Boehringer Ingelheim] has received final approval in Japan

Author：

ISSN： 1173-8324

Source： Inpharma, Vol.1, Iss.1465, 2004-01, pp. : 18-18

Disclaimer: Any content in publications that violate the sovereignty, the constitution or regulations of the PRC is not accepted or approved by CNPIEC.

Previous Menu Next

Abstract

Related content

Tiotropium bromide [Spiriva; Boehringer Ingelheim] and peginterferon- -2b plus ribavirin [Peg-Intron plus Rebetol; Schering-Plough] have been recommended for approval

Inpharma, Vol. 1, Iss. 1459, 2004-01 ,pp. : 22-22

Adis International

Access to resources Recommend Favorite

The average wholesale price (AWP) at which Pfizer and Boehringer Ingelheim are launching tiotropium bromide [Spiriva] is 30% less than the AWP of GlaxoSmithKline's salmeterol/fluticasone propionate [Advair]

PharmacoEconomics and Outcomes News, Vol. 1, Iss. 454, 2004-01 ,pp. : 11-11

Adis International

Access to resources Recommend Favorite

Wyeth has received a positive approval recommendation in Japan for etanercept [Enbrel]

Inpharma, Vol. 1, Iss. 1470, 2005-01 ,pp. : 20-20

Adis International

Access to resources Recommend Favorite

Novartis Pharma has received expanded approval in Japan for pamidronic acid

Inpharma, Vol. 1, Iss. 1471, 2005-01 ,pp. : 17-17

Adis International

Access to resources Recommend Favorite

Boehringer Ingelheim Canada has issued a `Dear Health Care Professional' letter regarding intracranial haemorrhage (ICH) in patients receiving Aptivus

Reactions Weekly, Vol. 1, Iss. 1110, 2006-01 ,pp. : 2-2

Adis International

Access to resources Recommend Favorite